Cancer patient explains how Kadcyla has extended her life
The National Institute for Health and Care Excellence has said women with breast cancer will not be able to have a new treatment on the NHS because it is too expensive.
Kadcyla costs around £90,000 per patient and extends the lives of women with advanced forms of the disease by an average of six months.
NICE Chief Executive Andrew Dillon said in a statement: "Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs."
Mother of four Hayley Kalinins, 33, has terminal cancer and has been on Kadcyla for 18 weeks after being given it through the cancer drug fund, which pays for a limited number of patients to use some treatments.
She told BBC Breakfast she was feeling well compared to previous chemotherapy treatments: "This is the miracle drug, this is the wonder drug, we need this."
08 Aug 2014